pharma · Diphtheria · Diabetes Mellitus, Type 2
Sanofi Pasteur MSD
Sanofi Pasteur
Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini
France, LYON HQ
363 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- France, LYON
- Employees
- 363
- Programs
- 83
- Drugs
- 66
- Patents
- 0
MEQ00073
Phase 3 · small molecule · Meningococcal infection
MEQ00073 for Meningococcal infection is a Phase 3 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Internal code MEQ00073
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi Pasteur
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Meningococcal infection
- Status
- active
- Trials
- 1